

**CLINICAL PREDICTORS FOR DEFIBRILLATION
THRESHOLDS MEASURED INTRAOPERATIVELY DURING
IMPLANTATION OF IMPLANTABLE-CARDIOVERTER
DEFIBRILLATORS**

A Thesis Submitted for Fulfillment of Medical Doctorate Requirements

**By
Dr Ahmed Abdellatif Hussein, MD
Under the Supervision**

Internal Supervisors from Cardiology Department

Cairo University School of Medicine

Prof Dr Medhat Elrefai, MD

Prof Dr Yasser Baghdaday, MD

Main External Supervisor from Cardiology Department

University of London School of Medicine

Prof. Dr John Camm, MD

Cairo university School of Medicine

University of London

2010

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"وَمَنْ أَحْيَاهَا فَكَأَنَّمَا أَحْيَا النَّاسَ جَمِيعًا"

سورة المائدة – آية ٣٢

**"And if anyone saved a life, it would be as if he saved the
life of all mankind "**

Surat Al-Ma'idah- Verse 32

Other Supervisors and Contributors

Dr Jaswinder Gill, MD, FRCP

Consultant of Cardiology and Cardiac Electrophysiology, St George's Hospital London, UK

Prof Dr Ulrika M. Birgersdotter-Green, MD

Cardiology Division University of California San Diego

Dr Imran Arif, MD

Assistant Professor, University of Cincinnati, Ohio, US

Dr Esam Baryun, MD

Cardiac Electrophysiologist St Mary's Hospital, Huntington, WV, US

Dr John Van Deren, MD, FACC

Cardiac Electrophysiologist St Mary's Hospital, Huntington, WV, US

Dr Thomas Bartlett, MD, FACC

Cardiac Electrophysiologist St Vincent Mercy Medical Center, Toledo, OH, US

Prof Dr Stephen Shorofsky, MD, PhD

Cardiac Electrophysiology Department, University of Maryland Medical Center, Baltimore, MD, US

Dr Magdi Saba, MD

Cardiac Electrophysiology Department, University of Maryland Medical Center, Baltimore, MD, US

Dr Timm Dickfeld, MD, PhD

Cardiac Electrophysiology Department, University of Maryland Medical Center, Baltimore, MD, US

Table of Contents

Dedication	6
Abstract	7
Part I: Review of Literature	
Chapter I: Introduction.....	10
Chapter II: Implantable Cardioverter Defibrillator and Lead Composition.....	30
Chapter III: Indications for Implantable Cardioverter-Defibrillator Therapy...	40
Chapter IV: Implantable Cardioverter-Defibrillator Sensing and Detection....	43
Chapter V: Basic Principles of Cardioversion and Defibrillation.....	55
Chapter VI: Defibrillation Threshold.....	67
Chapter VII: High DFT Problem: Predictors and Management.....	75
Aim of the study	87
Part II: Patients and Methods	
Chapter VIII: Patients and Methods.....	89
Part III: Results of the study	
Chapter IX: Results of the study.....	99
Part IV: Discussion and Limitations	
Chapter X: Discussion and Limitations.....	109
PART V: Summary and Conclusion	
Chapter XI: Summary and Conclusion.....	127
PART VI: REFERENCES	135
PART VII: MASTER TABLES	153
APPENDIX	163
ARABIC SUMMARY	180

List of Figures

Chapter I

Figure 1-1: An implantable cardioverter-defibrillator.....	13
Figure 1-2: Active and inactive ICD can.....	14
Figure 1-3: Initiation of reentry by a premature beat during spatially discordant alternans.....	23

Chapter II

Figure 2-1: Structure of implantable cardioverter-defibrillator.....	31
Figure 2-2: A bipolar ICD lead.....	34
Figure 2-3: A coaxial ICD lead.....	37
Figure 2-4: Passive Fixation Tined ICD Lead.....	38

Chapter IV

Figure 4-1: True bipolar and integrated bipolar ICD leads.....	49
Figure 4-2: Threshold start and decay delay programmable parameters for overcoming T wave oversensing.....	52
Figure 4-3: Programmer printout from one of our study patients.....	53

Chapter V

Fig 5-1: Diagrams indicating the spread of VF waves.....	57
Figure 5-2: a) Monophasic and b) Biphasic Defibrillation waveforms.....	62
Figure 5-3: The most widely used optimal biphasic waveform.....	64

Chapter VI

Figure 6- 1: Graphical representation of the relationship between probability of successful defibrillation versus energy level of shock.....	70
Figure 6-2: Bayesian Search Algorithm	73

Chapter VII

Figure 7-1: Shock Vector $AX > B$ versus $B > AX$	83
---	----

Chapter VIII

Figure 8-1: Common DFT testing algorithms.....	95
--	----

Chapter IX

Fig 9-1: Pie Chart showing groups I and II.....	102
Fig 9-2: Scatterogram plotting DFT against age.....	103
Figure 9-3: Scatterogram about the relation between DFT and LVEF.....	105
Figure 9-4: Prevalence of NICM in group I &II.....	106
Figure 9-5: The proportion of patients with LVEF of ≤ 26 in each group.....	106
Figure 9-6: The proportion of patients with pacing threshold of $\geq 0.8V$ in each group.....	107
Figure 9-7: Shows an episode of induced VF in a patient in our study group.....	108

Chapter XI

Figure 11-1: Diagram summarizing the distribution of males and females in the two study groups.	129
--	-----

List of Tables

Chapter I

Table 1-1: Implantable Cardioverter-Defibrillators NBD codes.....	20
---	----

Chapter III

Table 3-1: ICD Clinical Trials in Secondary Prevention of Ventricular Tachycardia and SCA.....	41
Table 3-2: ICD Clinical Trials in the Primary Prevention of VT and Sudden Cardiac Arrest.....	43

Chapter IV

Table 4-1: Causes of Undersensing.....	50
Table 4-2: Causes of Oversensing.....	51

Chapter VI

Table 6-1: Safety Margins for ICDs Based on DFT Method.....	71
---	----

Chapter VII

Table: 7-1: Clinical characteristics Related to ICD, ICD Leads and Implantation Procedure.....	81
--	----

Chapter IX

Table 9-1: Patient Demographics and Clinical Characteristics of Study population.....	99
Table 9-2: Electrocardiographic and Echocardiographic Characteristics.....	100
Table 9-3: ICD, Leads and Implantation Procedure Characteristics.....	101
Table 9-4: Pace/Sense Lead Measurements	
Table 9-5: Comparison between Continuous Variables in Group I and Group II.....	103

Table 9-6: Comparison between categorical Variables in Group I and Group II.....	104
Table 9-7: Result of Multivariate analysis of study variables.....	105
Table 9-8: Summary of the significant clinical predictors of high DFT in our study group.....	106
Table 9-9: A scoring system that predicts high DFT based on patient's clinical characteristics.	107

Dedication

This thesis is dedicated to Allah, the most gracious and the most merciful, to prophet Mohamed, peace be upon him, to my parents and my family.

Dr Ahmed Abdellatif Hussein

Abstract

Title: Clinical Predictors of Defibrillation Thresholds Measured Intraoperatively During Implantation of Implantable Cardioverter Defibrillators

Introduction Defibrillation Threshold Testing (DFT) testing is a lengthy, potentially painful, and a hazardous process. Little information is available concerning the identification of patients with high DFT who undergo ICD implantation with transvenous leads. Patients with predicted low DFTs may be eligible for abbreviated ICD testing but high-risk patients who require multiple shocks may require general anesthesia for patient comfort. Some suggested clinical characteristics that identify high DFT other than prior amiodarone use preoperatively. These include NYHA Class III, IV, low ejection fraction, no previous history of bypass surgery, and presenting with ventricular fibrillation. However, no specific recommendations have ever been suggested for DFT testing in patients having one or more high DFT predictors.

Aim of the Study: The aim of our study is to search for clinical predictors for defibrillation thresholds (DFTs) of implantable-cardioverter defibrillators (ICDs) in order to suggest the most suitable protocol for intraoperative testing for DFTs to reduce episodes of VF induction and subsequently reducing the number of shocks in the procedure, if possible.

Methods: Our study group comprised 50 consecutive patients who received ICDs for primary or secondary prevention of sudden cardiac arrest who were recruited in the period between January 2006 and December 2008 in St Thomas Hospital, University of London, London, UK, University of Maryland Medical Center, University of California San Diego Hospital, and St Vincent Mercy Medical Center, Toledo, Ohio. The study group mean age was 59 ± 13 year. The 50 patients included 31 male and 19 female. Thirty patients (60%) had hypertension, and 13 (26%) had diabetes Mellitus

Results: According to the measured DFT, the study group was subdivided into two groups; group I (n=42, 84%) with normal DFT defined as $DFT < 20J$ and group II (n=8, 16%) with high DFT defined as $DFT \geq 20J$. The continuous clinical variables which were used for comparison between groups I

and II included: age, body Surface Area (BSA), Body Mass Index (BMI), QRS complex duration, Left Ventricular Ejection Fraction (LVEF), R wave amplitude, RV Pacing threshold and Pace/sense lead impedance. Despite the trend of increase in DFT with the increase of age, there was no significant correlation between the two variables. Comparison between the two groups in terms of sex with more males in the high DFT group compared to lower DFT group. Also, patients in group II, with higher DFT, were more likely to have the diagnosis of dilated cardiomyopathy, have lower LVEF and were likely to receive 3 or more shocks during DFT testing. Multivariate regression analysis was conducted for the study group utilizing DFT as the dependent variable. Both pacing threshold and LVEF were found to correlate with DFT. It was found that pacing threshold had a negative correlation with DFT.

Conclusion: Our study demonstrated that the clinical variables of male sex, presence of non-ischemic cardiomyopathy, and higher degree of myocardial dysfunction reflected by lower LVEF and higher pacing thresholds may predict the group of patients who have higher DFT.

Key Words: Defibrillation Threshold, Implantable Cardioverter Defibrillators, Non-ischemic Dilated cardiomyopathy, Left Ventricular Ejection Fraction (LVEF).

PART I: REVIEW OF LITERATURE

CHAPTER I

INTRODUCTION

A HISTORICAL PERSPECTIVE

Despite advances in emergency medical systems and in techniques of resuscitation, sudden death from cardiac arrest remains a major public health problem. Most persons who have an out-of-hospital cardiac arrest do not survive (*Zipes and Wellens, 1998*). Those who are resuscitated may have severe, long-term cognitive impairment and motor impairment due to delays before a stable rhythm could be restored. In the 1970s, motivated by the death of a colleague, Drs. Michel Mirowski and Morton Mower, and their colleagues, developed the concept of an implantable device that could automatically monitor and analyze cardiac rhythm and deliver defibrillating shocks when it detected ventricular fibrillation (*Mirowski M et al, 1978*). The ICD was inspired by the success of prompt external defibrillation in terminating VF complicating acute myocardial infarction in the coronary care unit and by the high recurrence rate in patients resuscitated from out-of-hospital cardiac arrest. After Mirowski and Mower developed the first implantable prototype and they began testing in the animal lab, specifically with dogs. The system performed well in the canine tests, and could even recycle and deliver a second shock if the initial shock failed. In 1975 Mirowski and Mower made a film in which the implanted device resuscitated a dog from an induced VF (*Kenny T, 2006*).

After years of testing, in 1980 the first clinical implantation was performed in a young woman with recurrent ventricular fibrillation (*Mirowski M et al,*

1980). Early ICDs were primitive by current standards. The generators were bulky, nonprogrammable, and lacked shock synchronization capability. A thoracotomy was required to position at least one defibrillation patch epicardially (*vide infra*). The next generation of devices allowed programming of the rate and duration for arrhythmia detection, as well as of the initial shock energy. Several different manufacturers joined the first in researching, developing, and marketing ICD systems, accelerating the technological progress (*Pinski S and Chen P, 2002*). In the early 1990s; the advent of transvenous-subcutaneous defibrillation leads obviated the need for thoracotomy (*Saksena S and Parsonnet V, 1988*). The adoption of biphasic shock waveforms improved defibrillation efficiency, and the addition of extensive telemetric and diagnostic capabilities refined patient follow-up. Current ICDs deliver not only high-energy defibrillation shocks, but also low-energy shocks, antitachycardia pacing for VT, and pacing for bradyarrhythmias. They are less than 40 mL in size and are implanted transvenously with techniques similar to those used for implantation of standard pacemakers (*Pinski S and Chen P, 2002*).

More recently, randomized controlled trials have clarified the indications for ICD therapy. Subsequently, the implantable cardioverter-defibrillator evolved from a therapy of last resort for patients with recurrent cardiac arrest to a management standard for use in primary prevention and secondary prevention in patients with coronary heart disease (*DiMarco J, 2006*).